Anthem Biosciences IPO oversubscribed 4×

Anthem Biosciences, a CRDMO, closed its July 14–16 IPO with a 4.01× subscription, raising about ₹3,395 crore through an offer-for-sale. The strong investor interest reflects optimism in the biotech-manufacturing space. That said, analysts caution about regulatory and sector-specific risks.